Taysha Gene Therapies closed at $4.36 on Nov 4, up 6.60%, 37.5% below its 52-week closing high. Volume of 4.0M shares was 1.05× its 20-day average (close to normal).
Split-adjusted performance: -0.7% over one month, -37.5% over six months, -2.2% over one year.
Short interest was 51.2M shares at the Oct 15 settlement, down 6.9% from the prior report (17.6% of float, 11.6 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| TSHATaysha Gene Therapies | $4.36 | +6.60% | −37.5% | −100.0% | — | — | $1.42B | |
| INBXInhibrx Biosciences | $86.76 | +7.01% | −38.8% | −100.0% | — | — | $1.28B | Compare |
| VORVor Biopharma | $20.12 | +1.31% | +26.5% | — | — | 0.9 | $1.24B | Compare |
| NVAXNovavax | $10.65 | +10.02% | +13.8% | −76.3% | −94.2% | — | $1.76B | Compare |
| MAZEMaze Therapeutics | $33.38 | +3.50% | +26.1% | — | — | — | $1.85B | Compare |
| REPLReplimune Group | $20.69 | +0.19% | +501.5% | — | — | — | $1.96B | Compare |
| VIRVir Biotechnology | $11.77 | +4.90% | +14.4% | +19582.5% | 33.5% | — | $1.99B | Compare |
| BCRXBioCryst Pharmaceuticals | $8.24 | −3.85% | −6.7% | +33.6% | 35.9% | — | $2.11B | Compare |
| COAGHemab Therapeutics Holdings | $45.09 | +4.62% | — | — | — | — | $2.11B | Compare |
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
